4 registrations that name spermidine as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 4 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 4 registrations
RecruitingNCT07675200
Effects of Miricell Supplementation on Biomarkers of Healthy Aging and Autophagy
No phase
Nutraland USA, Inc.
About 70 people
Started Jan 9, 2026
In plain words A study of spermidine in people 40 to 70, run by Nutraland USA, Inc.. It plans to enroll about 70 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 70; healthy volunteers accepted. Conditions: Autophagy; Healthy Aging.
Provide voluntary signed and dated informed consent.
Be in fair health as determined by medical history and routine blood chemistries.
Age between the ages of 40 and 70 (inclusive).
Body weight of at least 110 pounds.
7 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Spermidine; Placebo
Registered summary
The goal of this clinical trial is to learn if a dietary supplement called Miricell works to improve cellular health and signs of healthy aging in adults. It will also learn about the safety of Miricell. The main questions it aims to answer are: * Does Miricell improve markers of autophagy, which is the body's natural process for recycling damaged cells? * Does Miricell support brain health, metabolic health, and visible signs of aging? * What medical problems, if any, do participants experience while taking Miricell? Researchers will compare Miricell to a placebo (a look-alike capsule that… The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07383311
Autophagy-Enhancers to Reduce Sleep Disturbances
No phase
University Medicine Greifswald
About 76 people
Started Oct 28, 2025
In plain words A study of spermidine in people 55 to 75, run by University Medicine Greifswald. It plans to enroll about 76 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 55 to 75; healthy volunteers accepted. Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease; Subjective Cognitive Decline (SCD).
Men and women
Written consent to participate in the study
German at native speaker level
Age between 55 and 75 years
13 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Spermidine Supplementation; Dietary Placebo
Registered summary
This clinical trial investigates the effects of spermidine supplementation on sleep quality and sleep-dependent memory consolidation in older adults with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI), two populations at increased risk of future cognitive decline and dementia. Impaired sleep has been identified as a modifiable factor contributing to cognitive decline, and interventions targeting sleep architecture could offer therapeutic potential to prevent or slow down this decline. The full summary is on the listing.
Where, as registered
No US site; Germany (1).
RecruitingNCT07035626
A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
Phase 1 and 2
West China Hospital
About 58 people
Started Jun 25, 2025
In plain words A Phase 1 and 2 study of spermidine in people 18 to 80, run by West China Hospital. It plans to enroll about 58 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Radiation-induced Xerostomia.
Patients with histopathologically confirmed head and neck squamous cell carcinoma (including nasopharyngeal carcinoma).
Aged ≥18 years and ≤80 years.
ECOG performance status score ≤2.
Receiving radical radiotherapy or concurrent chemoradiotherapy with radiation dose >50 Gy, where: Both parotid glands receive an average dose ≥25 Gy; or one gland receives a dose ≥25 Gy and the other receives any dose.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Spermidine; Spermidine simulants
Registered summary
This study is a single-center, double-blind, randomized controlled clinical trial with placebo as the control, aiming to evaluate the effectiveness of spermidine in preventing radiation-induced xerostomia during radiotherapy for head and neck tumors (including nasopharyngeal carcinoma).
Where, as registered
No US site; China (1).
RecruitingNCT07662330
Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia
No phase
Shanghai 10th People's Hospital
About 50 people
Started Jan 1, 2026
In plain words A study of spermidine in people 18 to 60, run by Shanghai 10th People's Hospital. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Obesity & Overweight; Hyperlipidemia.
Males or females aged 18 to 65 years.
BMI ≥ 24 kg/m², without severe chronic diseases.
Not currently using glucose-lowering or lipid-lowering medications.
Dyslipidemia defined as triglycerides ≥ 1.7 mmol/L or total cholesterol ≥ 5.2 mmol/L.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Spermidine; Placebo
Registered summary
Evaluate the effect of spermidine supplementation on lipid profile changes in individuals with overweight or obesity accompanied by hyperlipidemia. Analyze the impact of spermidine on metabolic parameters and assess the safety of spermidine supplementation, including liver and kidney function, gastrointestinal reactions, and other adverse effects.